Mexico receives 180,000 doses of Paxlovid drug to treat COVID-19 patients

Mexico receives 180,000 doses of Paxlovid drug to treat COVID-19 patients

The Health Secretary reported that Mexico received the first 180,000 of 300,000 medical treatments for specific use against COVID-19, trade name Paxlovid, which will be supplied from the following week.

We recommend you: COVID-19 cases fell 9% globally last week: WHO

Through a statement, the Health Secretary indicated that the drug Paxlovid it will be given free of charge to people with vulnerable health to reduce the risk of complications and hospitalization.

He explained that the combination of nirmatrelvir and ritonavir, whose trade name is Paxlovid, prevents SARS-CoV-2 from replicating, so it is recommended for people with mild or moderate symptoms of COVID-19 and at high risk of complications, he explained. dependency, he said.

“On April 22, the World Health Organization (WHO) declared that the combination of nirmatrelvir and ritonavir, whose trade name is Paxlovid, prevents SARS-CoV-2 from replicating, so it is recommended for people with mild or moderate picture of COVID-19 and with a high risk of complications “

In addition, the drug is included in the Clinical Guide for the treatment of COVID-19 in Mexico, updated in March 2022.

It will be supplied orally free of charge exclusively in public institutions, both federal and state health, according to the prioritization of groups at high risk of complications, progressively, according to the availability and deliveries of the producing laboratory, as well as progress in the distribution to care units predefined by each institution.

Health personnel were trained, from July 25 to 27, so that they know their application guidelines, interactions, pharmacovigilance, traceability and periodic report of use.

With N+ information

rare

Source: noticieros.televisa.com

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more

Leave a Reply

Your email address will not be published.